Twenty percent of NRAS mutant-driven melanoma patients had partial response to MEK inhibitor binimetinib in a phase II clinical trial.441 Similarly, targeting ERK kinase, the downstream effector of MEK, failed to show clinical benefits in treating RAS mutant cancer. The gene discussed is MAP2K7; the disease is melanoma.